The median is not the only message: A clinician's perspective on mathematical analysis of glycemic variability and modeling in diabetes mellitus

Journal of Diabetes Science and Technology

Volumn 3, Issue 1, 2009, Pages 3-11

  McCall, Anthony L ^a   Kovatchev, Boris P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Counterregulation; Glucagon; Hypoglycemia; Mathematical model; Variability

Indexed keywords

ARTICLE; BLOOD; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; THEORETICAL MODEL;

BLOOD GLUCOSE; DIABETES MELLITUS; HUMANS; MODELS, THEORETICAL;

EID: 77955421645     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300102     Document Type: Conference Paper

References (38)

1. CryerPE, DavisSN, ShamoonH. Hypoglycemia in diabetes. Diabetes Care. 2003;26(6):1902-12.
2. CryerPE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45(7):937-48.
3. Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44(8):968-83.
4. KhawKT, WarehamN, LubenR, BinghamS, OakesS, WelchA, DayN. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC≠Norfolk). BMJ. 2001;322(7277):15-8.
5. StrattonIM, AdlerAI, NeilHA, MatthewsDR, ManleySE, CullCA, HaddenD, TurnerRC, HolmanRR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
6. HirschIB, BrownleeM. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19(3):178-81.
7. LachinJM, GenuthS, NathanDM, ZinmanB, RutledgeBN, DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial - revisited. Diabetes. 2008;57(4):995-1001.
8. NathanDM, ClearyPA, backlundJY, GenuthSM, LachinJM, OrchardTJ, RaskinP, ZinmanB, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.
9. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet. 1998;352(9131):837-53.
10. HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577- 89.
11. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161(3):397-405.
12. EspositoK, GiuglianoD, NappoF, MarfellaR, Companion Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110(2):214-19.
13. MuggeoM, ZoppiniG, BonoraE, BrunE, BonadonnaRC, MoghettiP, VerlatoG. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care. 2000;23(1):45-50.
14. MeigsJB, NathanDM, D'AgostinoRB Sr., WilsonPW, Framingham Offspring Study. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25(10):1845-50.
15. TakeiY, TomiyamaH, TanakaN, YamashinaA. Close relationship between sympathetic activation and coronary microvascular dysfunction during acute hyperglycemia in subjects with atherosclerotic risk factors. Circ J. 2007;71(2):202-6.
16. ChiassonJL, JosseRG, GomisR, HanefeldM, KarasikA, LaaksoM, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486-94.
17. ChiassonJL, JosseRG, GomisR, HanefeldM, KarasikA, LaaksoM, STOP-NIDDM Trial Research Group. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data. Diabetologia. 2004;47(6):969-75.
18. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997;46(2):271-86.
19. KovatchevBP, CoxDJ, Gonder-FrederickLA, Young-HymanD, SchlundtD, ClarkeW. Assessment of risk for severe hypoglycemia among adults with IDDM: validation of the low blood glucose index. Diabetes Care. 1998;21(11):1870-5.
20. KovatchevBP, CoxDJ, Gonder-FrederickL, ClarkeWL. Methods for quantifying self-monitoring blood glucose profiles exemplified by an examination of blood glucose patterns in patients with type 1 and type 2 diabetes. Diabetes Technol Ther. 2002;4(3):295-303.
21. KovatchevBP, CoxDJ, KumarA, Gonder-FrederickL, ClarkeWL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther. 2003;5(5):817-28.
22. KovatchevBP, ClarkeWL, BretonM, BraymanK, McCallA. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol. Ther. 2005;7(6):849-62.
23. KovatchevBP, OttoE, CoxD, Gonder-FrederickL, ClarkeW. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29(11):2433-8.
24. KovatchevBP, StraumeM, CoxDJ, FarhyLS. Risk analysis of blood glucose data: A quantitative approach to optimizing the control of insulin dependent diabetes. J Theor Med. 2000;3(1):1-10.
25. KovatchevBP, CoxDJ, SummersKH, Gonder-FrederickL, ClarkeWL. Postprandial glucose dynamics and associated symptoms in type 2 diabetes mellitus. J Appl Res. 2003;3(4):449-58.
26. KovatchevBP, CoxDJ, KumarA, Gonder-FrederickL, ClarkeWL. Algorithmic evaluation of metabolic control and risk of severe hypoglycemia in type 1 and type 2 diabetes using self-monitoring blood glucose data. Diabetes Technol Ther. 2003;5(5):817-28.
27. RiddleMC, RosenstockJ, GerichJ, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26(11):3080-6.
28. HermansenK, DaviesM, DerezinskiT, Martinez RavnG, ClausonP, HomeP. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29(6):1269-74.
29. Action to Control Cardiovascular Risk in Diabetes Study Group, GersteinHC, MillerME, ByingtonRP, Goff DC Jr., BiggerJT, BuseJB, CushmanWC, GenuthS, Ismail-Beigi F, GrimmRH Jr., ProbstfieldJL, Simons-MortonDG, FriedewaldWT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
30. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72.
31. AbrairaC, DuckworthW, McCarrenM, EmanueleN, ArcaD, RedaD, HendersonW, VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus Type 2. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17(6):314-22.
32. MonnierL, MasE, GinetC, MichelF, VillonL, CristolJP, ColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7.
33. CoxD, Gonder-FrederickL, McCallA, KovatchevB, ClarkeW. The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycaemia and hyperglycaemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl. 2002;129:20-6.
34. CoxDJ, McCallA, KovatchevB, SarwatS, IlagLL, TanMH. Effects of blood glucose rate of changes on perceived mood and cognitive symptoms in insulin-treated type 2 diabetes. Diabetes Care. 2007;30(8):2001-2.
35. FarhyLS, DuZ, ZengQ, VeldhuisPP, JohnsonML, BraymanKL, McCallAL. Amplification of pulsatile glucagon secretion by switch-off of α-cell suppressing signals in Streptozotocin (STZ)-treated rats. Am J Physiol Endocrinol Metab. 2008;295:E575-85.
36. BergmanRN, IderYZ, BowdenCR, CobelliC. Quantitative estimation of insulin sensitivity. Am J Physiol. 1979;236(6):E667-77.
37. Dalla ManC, CaumoA, BasuR, RizzaR, ToffoloG, CobelliC. Measurement of selective effect of insulin on glucose disposal from labeled glucose oral test minimal model. Am J Physiol Endocrinol Metab. 2005;289(5):E909-14.
38. FarhyLS, McCallAL. System-level control to optimize glucagon counterregulation by switch-off of alpha-cell suppressing signals in beta-cell deficiency. J Diabetes Sci Technol 2009;3(1):21-33.